Dr. Graff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3303 Sw Bond Ave
Suite 7
Portland, OR 97239Phone+1 503-494-7999Fax+1 503-494-5385- Is this information wrong?
Education & Training
Oregon Health & Science UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009- Oregon Health & Science UniversityResidency, Internal Medicine, 2003 - 2006
George Washington University School of Medicine and Health SciencesClass of 2003
Certifications & Licensure
OR State Medical License 2006 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2012 Feb 06
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
- Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Start of enrollment: 2015 Oct 13
- Join now to see all
Publications & Presentations
PubMed
- Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.John Shen, Simon Chowdhury, Neeraj Agarwal, Lawrence I Karsh, Stéphane Oudard, Benjamin A Gartrell, Susan Feyerabend, Fred Saad, Christopher M Pieczonka, Kim N Chi, Sa...> ;British Journal of Cancer. 2024 Jan 1
- Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.Francesca Khani, William F Hooper, Xiaofei Wang, Timothy R Chu, Minita Shah, Lara Winterkorn, Michael Sigouros, Vincenza Conteduca, David Pisapia, Sara Wobker, Sydney ...> ;NPJ Precision Oncology. 2023 Nov 2
- Evolution of structural rearrangements in prostate cancer intracranial metastases.Francesca Khani, William F Hooper, Xiaofei Wang, Timothy R Chu, Minita Shah, Lara Winterkorn, Michael Sigouros, Vincenza Conteduca, David Pisapia, Sara Wobker, Sydney ...> ;NPJ Precision Oncology. 2023 Sep 13
- Join now to see all
Lectures
- Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resis...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- c15-148: Phase I/II trial of concurrent chemohormonal therapy using enzalutamide and cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Certain Toxic Effects Higher with Newer Prostate Cancer TherapiesMay 26th, 2023- Genetic Testing – the New Standard in Treatment for Advanced Prostate CancerJuly 6th, 2021
- Desert Storm Veteran in New Battle with Prostate CancerMarch 5th, 2021
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Portland HCSPortland, Oregon
OHSU HospitalPortland, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
